GlassScriptPhysician profile
Janelle Shah
NPI 1114419280
$10,473.62
in general payments reported to CMS, 2019-2025
31 companies · $4,617 in 2025
The $4,617 reported for 2025 was more than what 99% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,368 · 2022: $981 · 2023: $873 · 2024: $2,636 · 2025: $4,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,058 · Travel and Lodging: $2,022 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,057.94 |
| Travel and Lodging | $2,022.02 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,405.38 | 2024-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $2,151.28 | 2022-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Abbvie INC. | $1,149.97 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,016.39 | 2021 | |
| Scilex Pharmaceuticals INC. | $832.78 | 2021-2025 | Ztlido |
| Abbott Laboratories | $620.94 | 2023-2025 | Proclaim, Eterna |
| Collegium Pharmaceutical, INC. | $502.01 | 2022-2025 | Xtampza, Belbuca |
| Indivior INC. | $353.90 | 2023-2025 | Sublocade |
| Pfizer INC. | $339.21 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $241.89 | 2022 | |
| Horizon Therapeutics Plc | $114.67 | 2021-2022 | |
| Averitas Pharma INC. | $92.30 | 2023-2025 | Qutenza |
| Nevro Corp. | $85.62 | 2022-2024 | Senza |
| Lilly USA, LLC | $63.69 | 2021 | |
| Vertos Medical, INC. | $61.10 | 2023 | Mild Device Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.81 | 2022-2024 | Relistor |
| Vertex Pharmaceuticals Incorporated | $55.80 | 2024-2025 | |
| Protega Pharmaceutials INC | $53.22 | 2024 | Roxybond |
| Hikma Pharmaceuticals USA | $39.48 | 2021-2022 | |
| Almatica Pharma LLC | $35.54 | 2022 | |
| Allergan, INC. | $28.48 | 2022 | |
| Spinal Simplicity, LLC | $24.41 | 2025 | Ha Minuteman G3-R |
| Redhill Biopharma INC. | $21.04 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $19.31 | 2023 | Iovera, Zilretta, Exparel |
| Amgen INC. | $19.10 | 2022 | |
| Bioventus LLC | $18.93 | 2025 | Bonescalpel & Sonicone (O.R.) |
| International Rehabilitative Sciences, INC | $14.82 | 2024 | Rs 4i Plus Sequential Stimulator |
| Grt US Holding, INC. | $14.61 | 2022 | |
| Fidia Pharma USA INC. | $14.30 | 2025 | Triluron, Hymovis |
| Biodelivery Sciences International, INC. | $14.10 | 2021 | |
| Lundbeck LLC | $13.54 | 2025 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janelle Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.